To Succeed Commercially, Newer Players are Taking a Focused Approach to Needle-free Injection

New Survey by Greystone Associates Analyzes the Shifting Competitive Landscape and the Evolution of NFI Business Models

[USPRwire, Thu Mar 18 2010] For a number of technical, economic and strategic reasons, needle-free injection (NFI) remains a niche technology where commercial success continues to be elusive. The pure play drug delivery firms that have attempted to follow a technology-based business model – companies such as Antares Pharma and Bioject - have fared poorly, in large part due to intense competition from competing injection devices such as pen injectors and autoinjectors that stole much of NFI’s perceived advantage. Unable to adjust quickly enough to the shifting competitive environment, these companies have been acquired, diversified into more commercially viable delivery platforms, and/or been forced to repeatedly restructure and reduce staff to survive.

A younger group of companies, mostly private firms that seek to develop NFI products strategically using a product-based model, are faring better. They seek to develop drug-device combination products based on NFI through the clinical trial process. This group is exemplified by companies such as Zogenix and Glide Pharma. In terms of look and feel, these bundled devices mimic many of the pen and autoinjector achievements, and provide product differentiation that has become critical in the direct-to-consumer marketing era. While light-weight and ergonomic designs that represent a new generation in NFI devices improve the chances of technology-based NFI business models succeeding commercially, the product-based model is here to stay.

A new analysis from Greystone Associates examines the current and future demand for needle-free injectors and identifies key factors that will influence the direction of this market sector.

More information is available at www.greystoneassociates.org .

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Contact:

Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org

Source: Greystone Associates